| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3992435 | Journal of Thoracic Oncology | 2008 | 6 Pages |
Abstract
Patients with HER2 FISH-positive LA-NSCLC had a poorer outcome even when treated with cisplatin-based chemoradiotherapy, despite the strong need for validation assessment of these observations. Development of more effective treatment for these high-risk patients is needed to improve their poor prognosis.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Shoichi MD, Katsuyuki MD, PhD, Masahiro MD, PhD, Yoshihiko MD, PhD, Yoshiro MD, Nagio MD, PhD, Katsuyuki MD, PhD, Hiroshi MD, PhD, Kenji MD, PhD, Mitsune MD, PhD,